CRSP:NASDAQ
Crispr Therapeutics AG
55,43 $US
arrow_downward
-0,02%(-0,0100) 1J
55,30 $US
arrow_downward
-0,23% (-0,13)bedtimeAprès clôture
Fermé : 2 oct., 16:00:01 UTC−4 · USD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour CRSP...
Ouverture
56,45 $US
Élevé
57,58 $US
Faible
54,09 $US
Cap. boursière
5,36 Md
Vol. moyen
1,60 M
Volume
1,13 M
+ haut sur 1 an
78,48 $US
+ bas sur 1 an
44,12 $US
BPA
-4,76 $US
Bêta
1,45
Actions en circulation
96,69 M
Nombre d'employés
393
Ouverture
56,45 $US
Élevé
57,58 $US
Faible
54,09 $US
Cap. boursière
5,36 Md
Vol. moyen
1,60 M
Volume
1,13 M
+ haut sur 1 an
78,48 $US
+ bas sur 1 an
44,12 $US
BPA
-4,76 $US
Bêta
1,45
Actions en circulation
96,69 M
Nombre d'employés
393
Articles
Sources : Web et partenaires du secteur de l'information
Simply Wall Street
·
il y a 1 jour
CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base
Barchart.com
·
il y a 3 jours
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.
Profil
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
À propos de Crispr Therapeutics AG
PDGSamarth Kulkarni
Employés393
Date de création2013
Siège socialZoug, Zoug, Suisse
Secteur-
Site Webcrisprtx.com